News and Announcements
Proteomics International Raises $1.44 Placement and Now Offering a Share Purchase Plan
- Published February 06, 2017 4:11PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International is a specialist innovation-driven medical technology company based in Perth, Western Australia.
- Focused on the area of proteomics- the industrial scale study of the structure and functions of proteins.
- Established in 2001, providing services to groups throughout the Indo-Asian region. They consider themselves and are recognised as global leaders in their field of work.
Medtech company, Proteomics International Laboratories Ltd (PILL), is pleased to announce it has finalised the first phase of a targeted capital raising by placement of 6m shares at $0.24 to raise $1.44m. The oversubscribed “Placement” raised $1.44 million with the support from existing and new sophisticated investors.
The Placement received strong support overall from existing and new sophisticated investors and was significantly over-subscribed. The Placement was priced at $0.24 per share, with a discount of 12.7% to the last sale price. Proteomics also announced a Share Purchase Plan (SPP) to existing shareholders to raise $480, 000 at $0.24 per share. With K S Capital Pty Ltd acting as a Lead Manager to the Placement.
PILL recently announced important developments in both its areas of operation, Diagnostics and Analytical Services. The Board considered that these activities could be enhanced by an injection of capital.
The funds will therefore be used to contribute support to:
- The commercialisation and product development of PILLS’s flagship diagnostic product, PromarkerD, a breakthrough predictive test for diabetic kidney disease; and
- The roll-out of PILL’s new analytical testing services, in conjunction with Linear Clinical Research, for the fast-growing clinical trials market.
From the Placement, $500,000 has been allocated to each area, with the balance for working capital. Funds raised under the SPP will be distributed equally between the areas of diagnostics, analytical services and working capital. By fast-tracking its programs PILL seeks to bring forward its potential commercialisation deals for PromarkerD, and to expand sales from analytical services. Both areas continue to push the company towards cash-flow and positive operations.
To read the full announcement, please click here.
Company Updates
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Backed By Leading Investment Groups and Family Offices
